Response to: Comparison of infliximab drug measurement across three commercially available ELISA kits

Pathology. 2017 Apr;49(3):332-334. doi: 10.1016/j.pathol.2017.01.004. Epub 2017 Mar 6.

Authors

D Nagore¹, N Rapún², I Antón², J Harper³, A Martínez⁴

Affiliations

¹ R&D Department, Progenika Biopharma-Grifols, Derio, Spain. Electronic address: daniel.nagore@progenika.grifols.com.
² Product Development and Support, Progenika Biopharma, Derio, Spain.
³ Australia National Applications, Grifols Australia Ltd, Melbourne, Vic, Australia.
⁴ R&D Department, Progenika Biopharma-Grifols, Derio, Spain.

PMID: 28274669
DOI: 10.1016/j.pathol.2017.01.004

No abstract available

Publication types

Letter
Comment

MeSH terms

Enzyme-Linked Immunosorbent Assay*
Humans
Infliximab*
Reagent Kits, Diagnostic

Substances

Reagent Kits, Diagnostic
Infliximab